About Index Trending news
Analyze
Pricing
Trevi Therapeutics

Trevi Therapeutics

Work at Trevi Therapeutics? Add yourself to this profile

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Edit Profile
More info

Elsewhere

Contributors to this profile

Companies in the same industry

23andMe 23andMe Blue Belt Technologies Blue Belt Technologies Glowing Plant Glowing Plant LabCentral LabCentral Green Biologics Green Biologics Chiasma Chiasma Ventripoint Ventripoint The Medical Memory by ClarIT-MD The Medical Memory by ClarIT-MD leon-nanodrugs leon-nanodrugs PHEMI Systems PHEMI Systems

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 4
Add info
20 Jul 2017
$50,500,000
Venture capital (Series C)
Omega Funds, TPG Biotechnology Partners, Aperture Venture Partners, +2

NEA leads $50.5 mln Series C round in Trevi Therapeutics

PE Hub
08 Jan 2015
$15,000,000
Debt financing
Square 1 Bank, Solar capital

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor

abladvisor
06 Nov 2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec 2012
$6,564,102
Venture capital